Your Yourlocation: Home > Long-acting β2 agonists and tiotropium bromide(136310-93-5): which is better

Long-acting bronchodilators, including long-acting β2 receptor agonists (LABA) and anticholinergic drugs tiotropium bromide(136310-93-5), are currently recommended for first-line maintenance regimens in patients with chronic obstructive pulmonary disease (COPD).

Several observational studies and randomized controlled studies have compared the safety and efficacy of tiotropium bromide and LABA, but have come to conflicting conclusions.

According to Suissa Scholar, Department of Epidemiology and Health Statistics, McGill University, Montreal, Canada, the initial use of tiotropium does not increase the risk of cardiovascular and cerebrovascular events, but can reduce the incidence of pneumonia compared to LABA. The article was published on the recently published Chest.

The observational cohort study retrieved COPD patients in the UK Clinical Practice Study Database (CPRD) from September 25, 2003 to August 31, 2012, all patients aged 55 years or older who were recently using long-acting bronchodilators.

The COPD patients who started using LABA and COPD patients who started using tiotropium bromide(136310-93-5) were tested based on the subject's tendency score and previous use of inhaled glucocorticoid (ICS). All subjects were followed up for one year. The study assessed the incidence of acute myocardial infarction (AMI), stroke, heart failure, arrhythmia and pneumonia in subjects during the year.

A total of 26,442 COPD patients with tiotropium bromide(136310-93-5) were recruited and 26442 COPD patients who started using LABA were recruited. The two groups of subjects were well matched on the prospective score and past ICS use.

The study found that the initial use of tiotropium bromide or the initial use of LABA treatment of COPD patients, the incidence of cardiovascular adverse events within a year similar to the incidence.

Compared with COPD patients who started using LABA, the risk of AMI was 1.10, the HR of stroke was 1.02, the HR of arrhythmia was 0.81, and the onset of COPD in patients treated with tiotropium, Heart failure HR is 0.90.

The study found that, compared with the beginning of the use of LABA patients with COPD, the initial use of tiotropium bromide(136310-93-5) in COPD patients, the use of 1 year of pneumonia risk decreased significantly, HR 0.81.

The results suggest that COPD patients with long-term maintenance of long-acting bronchodilator: LABA and tiotropium bromide(136310-93-5), with similar cardiovascular and cerebrovascular safety. Tiotropium does not increase the risk of cardiovascular adverse events; compared with LABA, tiotropium can significantly reduce the risk of pneumonia.

This risk difference confirms the advantages of tiotropium, a long-acting bronchodilator, in the safety of patients with COPD.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved